AxoGen (AXGN)
NASDAQ:AXGN
Want to see AXGN full AI Analyst Report?
AXGN Stock Chart & Stats
$38.50
>-$0.01(>-0.01%)
At close: 4:00 PM EST
$38.50
>-$0.01(>-0.01%)
Day’s Range― - ―
52-Week Range$9.22 - $45.83
Previous CloseN/A
Volume66.42K
Average Volume (3M)801.93K
Market Cap
$2.10B
Enterprise Value$2.04B
Total Cash (Recent Filing)$82.65M
Total Debt (Recent Filing)$20.64M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Aug 12, 2026EPS Estimate
0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.63
Shares Outstanding53,177,822
10 Day Avg. Volume462,742
30 Day Avg. Volume801,935
Financial Highlights & Ratios
PEG Ratio-2.01
Price to Book (P/B)11.70
Price to Sales (P/S)6.69
P/FCF Ratio-513.89
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue8.56
Enterprise Value/Gross Profit11.41
Enterprise Value/Ebitda357.82
Forecast
1Y Price Target
$50.14Price Target Upside30.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)0.5
Revenue Forecast (FY)$270.85M
Bulls Say, Bears Say
Bulls Say
High Gross Margins & Improving ProfitabilitySustained gross margins near 74% provide structural profitability leverage: as procedure volumes rise, incremental revenue will largely flow to operating margin. Positive EBITDA indicates the core model can scale to operating profitability, reducing reliance on financing for near-term operations.
Strengthened Liquidity And Lower LeverageAn upsized equity raise and full repayment of the Oberland loan materially bolster liquidity and reduce refinancing risk. A stronger cash position and modest outstanding debt provide flexibility to fund commercialization, surgeon training, and R&D without immediate pressure to raise capital.
Improved Reimbursement & CoverageA new CMS code and positive commercial insurer decisions improve procedure economics and reduce barriers for hospital adoption. Durable reimbursement expansion enhances unit economics for Avance, supports broader surgeon uptake, and creates a foundation for more predictable revenue growth.
Bears Say
Ongoing Net LossesDespite operational improvements, persistent net losses mean returns on equity remain negative and the company hasn't converted scale into consistent bottom-line profit. Continued losses could constrain reinvestment, pressure margins under stress, or require future capital raises.
Volatile Cash Flow HistoryRecent positive free cash flow marks progress, but historical volatility in cash conversion signals inconsistent underlying cash-generative capacity. This variability complicates multi-quarter planning for commercialization spend and raises the probability of needing external financing during adverse periods.
Slowing Revenue Growth RateRevenue growth decelerated to mid-single digits from prior double-digit expansion, which limits near-term operating leverage and extends the timeline to durable profitability. Slower top-line momentum may signal market saturation in core segments or the need for new indications to sustain growth.
AxoGen News
AXGN FAQ
What was AxoGen’s price range in the past 12 months?
AxoGen lowest stock price was $9.21 and its highest was $45.83 in the past 12 months.
What is AxoGen’s market cap?
AxoGen’s market cap is $2.10B.
When is AxoGen’s upcoming earnings report date?
AxoGen’s upcoming earnings report date is Aug 12, 2026 which is in 69 days.
How were AxoGen’s earnings last quarter?
AxoGen released its earnings results on Apr 28, 2026. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.075 by -$0.005.
Is AxoGen overvalued?
According to Wall Street analysts AxoGen’s price is currently Undervalued.
Does AxoGen pay dividends?
AxoGen pays a Notavailable dividend of $1 which represents an annual dividend yield of N/A. See more information on AxoGen dividends here
What is AxoGen’s EPS estimate?
AxoGen’s EPS estimate is 0.12.
How many shares outstanding does AxoGen have?
AxoGen has 53,177,822 shares outstanding.
What happened to AxoGen’s price movement after its last earnings report?
AxoGen reported an EPS of $0.07 in its last earnings report, missing expectations of $0.075. Following the earnings report the stock price went up 6.601%.
Which hedge fund is a major shareholder of AxoGen?
Currently, no hedge funds are holding shares in AXGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AxoGen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.14 (30.24% Upside)
$50.14 (30.24% Upside)
Hedge Fund Trend
Increased
By 24.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
89.02%
12-Months-Change
Fundamentals
Return on Equity
-20.74%
Trailing 12-Months
Asset Growth
47.57%
Trailing 12-Months
Company Description
AxoGen
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
AXGN Company Deck
AXGN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents materially positive operational and strategic progress: robust revenue growth (Q4 +21.3% YoY; FY +20.2% YoY), a strong capital raise and debt retirement, positive adjusted EBITDA and cash flow for the year, and a transformative FDA BLA approval that establishes Avance as the reference biologic. Near-term challenges include one-time BLA-related noncash charges, elevated operating expenses (notably R&D and G&A), a Q4 net loss and short-term gross margin pressure as the product mix shifts to the biologic. Management provided prudent guidance (≥18% revenue growth for 2026) and expects margin recovery in 2027 as scale and process improvements are implemented. Overall, the highlights outweigh the lowlights given the regulatory milestone, healthy top-line growth, improved adjusted EBITDA and strengthened balance sheet, supporting a constructive outlook despite short-term cost pressure.View all AXGN earnings summariesAXGN Stock 12 Month Forecast
Average Price Target
$50.14
▲(30.24% Upside)
Technical Analysis
Ownership Overview
1.57% Insiders
19.33% Mutual Funds
45.79% Other Institutional Investors
19.61% Public Companies and
Individual Investors